普洛藥業(000739.SZ):左氧氟沙星片擬中選第四批全國藥品集中採購
格隆匯 2 月 3日丨普洛藥業(000739.SZ)公佈,2021年2月3日,公司參加了聯合採購辦公室(“聯採辦”)組織的第四批全國藥品集中採購,公司左氧氟沙星片擬中選本次集中採購。
擬中選價格:17.02元/盒(7片/盒);擬供應地區:山東、安徽、新疆(含兵團)、貴州;本輪採購週期:三年。
公司左氧氟沙星片於2020年10月份以化藥新四類註冊通過審評並獲得國家藥監局簽發的《藥品註冊批件》(視同通過仿製藥一致性評價),截止此次集採前,該產品已有一定量的銷售。
此次集中採購是國家組織的第四批藥品集中帶量採購,採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量。若公司後續簽訂採購合同並實施後,將有利於公司左氧氟沙星片的快速放量銷售,有利於該產品國內市場的開拓,提升公司品牌影響力,對公司未來經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.